Galapagos - Model GLPG0778/555 - JAK1 Inhibitor - Osteoarthritis
GlaxoSmithKline exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK has all rights to these compounds, and Galapagos is eligible to receive milestones and up to double-digit royalties on global sales. In the course of 2013, GSK initiated Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus, chronic plaque psoriasis, and ulcerative colitis. In February 2014, GSK stopped the lupus study due to a lack of effect and put the ulcerative colitis study on hold. In April 2014,
GSK informed Galapagos that GSK2586184 met the primary endpoint in a Phase 2a study in psoriasis. In August 2014, GSK informed Galapagos that they have assessed the overall risk:benefit profile of GSK2586184 and have elected to terminate all indications where GSK 2586184 is administered orally for chronic immuno-inflammatory disease (SLE, psoriasis, ulcerative colitis). Development options for GSK2586184 in other potential indications are presently being explored by GSK.